- Moderna Inc MRNA has completed the rolling submission process for its marketing application to the FDA, seeking full licensure of its COVID-19 vaccine.
- The application is for active immunization to prevent COVID-19 in individuals 18 years of age and older. Moderna has requested Priority Review designation.
- In the final analysis of Phase 3 COVE study data, the Moderna COVID-19 vaccine showed 93% efficacy, with the effectiveness remaining durable through six months.
- Related: Moderna COVID-19 Shot Is 93% Effective After Six Months Of Second Dose.
- In June, Moderna also filed for an Emergency Use Authorization (EUA) for adolescents ages 12 and above with the FDA.
- Related: FDA Asks Pfizer/BioNTech, Moderna To Expand COVID-19 Vaccine Trials In Children
- Related content: Benzinga's Full FDA Calendar.
- Price Action: MRNA stock is up 2.09% at $403.21 during the market session on the last check Wednesday.
- Photo by Spencer Davis from Pixabay
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted In:
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
